Pharmacodynamics of PEG-IFN alpha-2a in HIV/HCV co-infected patients: Implications for treatment outcomes

Benzer Materyaller

• Pharmacodynamics of PEG-IFN alpha-2a and HCV response as a function of IL28B polymorphism in HIV/HCV co-infected patients
  Yazar:: de Araújo, Evaldo Stanislau Affonso, ve diğerleri
  Baskı/Yayın Bilgisi: (2011)
• Very early prediction of response to HCV treatment with peg-IFN-alfa-2a and ribavirin in HIV/HCV coinfected patients
  Yazar:: Araújo, Evaldo Stanislau A., ve diğerleri
  Baskı/Yayın Bilgisi: (2011)
• Therapeutic Response to Peg IFN-alpha-2b and Ribavirin in HIV/HCV Co-infected African American and Caucasian Patients as a function of HCV Viral Kinetics and Interferon Pharmacodynamics
  Yazar:: Rozenberg, L, ve diğerleri
  Baskı/Yayın Bilgisi: (2009)
• Understanding triphasic HCV decline during treatment in the era of IL28B polymorphisms and direct acting antiviral agents via mathematical modeling
  Yazar:: Dahari, Harel, ve diğerleri
  Baskı/Yayın Bilgisi: (2012)
• Hepatitis C Viral Kinetics During Treatment With Peg IFN-alpha-2b in HIV/HCV Co-Infected Patients as a Function of Baseline CD4(+) T Cell Counts
  Yazar:: Avidan, Neumann U., ve diğerleri
  Baskı/Yayın Bilgisi: (2009)